Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

医学 前列腺癌 前列腺癌的治疗 投票 前列腺 德尔菲法 疾病 肿瘤科 妇科 癌症 内科学 家庭医学 法学 统计 政治 数学 政治学
作者
Silke Gillessen,Gerhardt Attard,Tomasz M. Beer,Himisha Beltran,Alberto Bossi,Robert G. Bristow,Brett S. Carver,Daniel Castellano,Byung Ha Chung,Noel W. Clarke,Gedske Daugaard,Ian D. Davis,Johann S. de Bono,Rodolfo Borges dos Reis,Charles G. Drake,Rosalind Eeles,Eleni Efstathiou,Christopher P. Evans,Stefano Fanti,Felix Y. Feng,Karim Fizazi,Mark Frydenberg,Martin Gleave,Susan Halabi,Axel Heidenreich,Celestia S. Higano,Nicholas D. James,Philip W. Kantoff,Pirkko–Liisa Kellokumpu-Lehtinen,Raja B. Khauli,Gero Kramer,C. Logothetis,Fernando C. Maluf,Alicia K. Morgans,Michael J. Morris,Nicolas Mottet,Vedang Murthy,William Oh,Piet Ost,Anwar R. Padhani,Chris Parker,Colin C. Pritchard,Mack Roach,Mark A. Rubin,Charles J. Ryan,Fred Saad,Oliver Sartor,Howard I. Scher,Avishay Sella,Neal D. Shore,Matthew R. Smith,Howard R. Soule,Cora N. Sternberg,Hiroyoshi Suzuki,Christopher J. Sweeney,Matthew R. Sydes,Ian F. Tannock,Bertrand Tombal,Riccardo Valdagni,Thomas Wiegel,Aurelius Omlin
出处
期刊:European Urology [Elsevier BV]
卷期号:73 (2): 178-211 被引量:522
标识
DOI:10.1016/j.eururo.2017.06.002
摘要

In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level of evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some of these topics. To present the report of APCCC 2017. Ten important areas of controversy in APC management were identified: high-risk localised and locally advanced prostate cancer; “oligometastatic” prostate cancer; castration-naïve and castration-resistant prostate cancer; the role of imaging in APC; osteoclast-targeted therapy; molecular characterisation of blood and tissue; genetic counselling/testing; side effects of systemic treatment(s); global access to prostate cancer drugs. A panel of 60 international prostate cancer experts developed the program and the consensus questions. The panel voted publicly but anonymously on 150 predefined questions, which have been developed following a modified Delphi process. Voting is based on panellist opinion, and thus is not based on a standard literature review or meta-analysis. The outcomes of the voting had varying degrees of support, as reflected in the wording of this article, as well as in the detailed voting results recorded in Supplementary data. The presented expert voting results can be used for support in areas of management of men with APC where there is no high-level evidence, but individualised treatment decisions should as always be based on all of the data available, including disease extent and location, prior therapies regardless of type, host factors including comorbidities, as well as patient preferences, current and emerging evidence, and logistical and economic constraints. Inclusion of men with APC in clinical trials should be strongly encouraged. Importantly, APCCC 2017 again identified important areas in need of trials specifically designed to address them. The second Advanced Prostate Cancer Consensus Conference APCCC 2017 did provide a forum for discussion and debates on current treatment options for men with advanced prostate cancer. The aim of the conference is to bring the expertise of world experts to care givers around the world who see less patients with prostate cancer. The conference concluded with a discussion and voting of the expert panel on predefined consensus questions, targeting areas of primary clinical relevance. The results of these expert opinion votes are embedded in the clinical context of current treatment of men with advanced prostate cancer and provide a practical guide to clinicians to assist in the discussions with men with prostate cancer as part of a shared and multidisciplinary decision-making process.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xiao完成签到,获得积分10
1秒前
兔兔完成签到,获得积分10
1秒前
2秒前
聪明的秋天完成签到,获得积分10
3秒前
moexce完成签到,获得积分10
3秒前
离研通完成签到,获得积分10
4秒前
灵波发布了新的文献求助10
5秒前
ao黛雷赫完成签到,获得积分10
5秒前
原料药研发粗人完成签到,获得积分10
6秒前
yyn发布了新的文献求助10
6秒前
8秒前
9秒前
乐乐的应助被欧阳峰采纳,获得10
9秒前
LW3366完成签到,获得积分10
10秒前
ding的应助被科研通管家采纳,获得10
11秒前
CodeCraft的应助被科研通管家采纳,获得30
11秒前
共享精神的应助被科研通管家采纳,获得10
11秒前
慕青的应助被科研通管家采纳,获得10
12秒前
科研通AI2S的应助被科研通管家采纳,获得10
12秒前
李爱国的应助被科研通管家采纳,获得10
12秒前
12秒前
李爱国的应助被科研通管家采纳,获得10
12秒前
12秒前
无极微光的应助被科研通管家采纳,获得20
12秒前
DW的应助被科研通管家采纳,获得10
12秒前
勤奋一一的应助被科研通管家采纳,获得10
12秒前
13秒前
wanci的应助被科研通管家采纳,获得10
13秒前
传奇3的应助被科研通管家采纳,获得10
13秒前
搜集达人的应助被科研通管家采纳,获得10
13秒前
隐形曼青的应助被科研通管家采纳,获得10
13秒前
剪刀手发布了新的文献求助10
13秒前
研友_VZG7GZ的应助被gentle采纳,获得10
13秒前
ding的应助被科研通管家采纳,获得10
13秒前
sheey的应助被科研通管家采纳,获得30
13秒前
香蕉觅云的应助被科研通管家采纳,获得10
13秒前
杜欣悦完成签到,获得积分20
13秒前
coolru的应助被科研通管家采纳,获得10
14秒前
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621